US62855J1043 - Common Stock
MYRIAD GENETICS INC
NASDAQ:MYGN (4/19/2024, 7:05:53 PM)
After market: 18.5 0 (0%)18.5
-0.01 (-0.05%)
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,600 full-time employees. The firm provides testing that helps assess an individual’s risk for developing disease or disease progression and guides treatment decisions across medical specialties where genetic insights can significantly improve patient health care and lower health care costs, and includes corporate services, such as finance, human resources, legal and information technology. The company has three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. Its products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, and EndoPredict, Foresight, Prequel, and SneakPeek and GeneSight.
MYRIAD GENETICS INC
322 North 2200 West
Salt Lake City UTAH 84108
P: 18015843600
CEO: R. Bryan Riggsbee
Employees: 2600
Website: https://myriad.com/
80% of people diagnosed with anxiety, depression report losing years or decades of time
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...
Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight test
Here you can normally see the latest stock twits on MYGN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: